INVESTORS & MEDIA

News Release

September 1, 2016 at 9:30 AM EDT

Regeneron Announces Upcoming 2016 Investor Conference Presentations

TARRYTOWN, N.Y., Sept. 1, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conferences:        

  • 2016 Credit Suisse Antibody Day at 10:00 a.m. Eastern Time on Wednesday, September 7, 2016
  • Morgan Stanley Global Healthcare Conference at 11:40 a.m. Eastern Time on Monday, September 12, 2016
  • Bank of America Merrill Lynch Global Healthcare Conference at 6:25 a.m. Eastern Time on Wednesday, September 14, 2016

The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases, high LDL-cholesterol, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. For additional information about the Company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:                 

Investor Relations                                                         Corporate Communications     
Manisha Narasimhan, Ph.D.                                          Hala Mirza
914.847.5126                                                               914.847.3422     
manisha.narasimhan@regeneron.com                           hala.mirza@regeneron.com  

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-2016-investor-conference-presentations-300321354.html

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media